⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 16, 2024

Figure S9 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Sun Min Lim Toshio Fujino Chulwon Kim Gwanghee Lee Yong-Hee Lee Dong‐Wan Kim Jin Seok Ahn Tetsuya Mitsudomi Taiguang Jin Sang-Yoon Lee

View at Publisher

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplementary Figure 9. Circulating tumor DNA analysis data from Case 2. A, Allelic configuration of T790M (red), L792H (green) and C797S (blue). B, Serial changes in allelic frequency of mutations detected in blood. C, Concentration-response curves and IC50 values of BBT-176 for EGFR 19Del/T790M/L792H mutant kinase.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523773 https://doi.org/10.1158/1078-0432.27031999

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
2Figure S6 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
3Figure S4 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
4Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
5Figure S1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
6Figure S2 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
7Figure S10 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
8Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024